研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400016[3]The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,China,510000[4]Peking University Shenzhen Hospital,Shenzhen,Guangdong,China,518036[5]Hospital workers in Liuzhou,Liuzhou,Guangxi,China,545000[6]WuHan Jinyintan Hospital,WuHan,Hubei,China,430023[7]The Second XIANGYA Hospital Of Central South University,Changsha,Hunan,China,410008[8]The Fifth People's Hospital of Wuxi (Affiliated Wuxi Fifth Hospital of Jiangnan University),Wuxi,Jiangsu,China,214001[9]The first hospital of Jilin University,Changchun,Jilin,China,130021[10]The Sixth People's Hospital of Shenyang,Shenyang,Liaoning,China,110000[11]The First Affiliated Hospital of Xi'an Jiao Tong University,Xi'an,Shaanxi,China,710000[12]West China Hospital of Sichuan University,Chengdu,Sichuan,China,610044[13]The First Affiliated Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China,831400[14]First People's Hospital of Yunnan Province,Kunming,Yunnan,China,650034[15]Pu'er People's Hospital,Pu'er,Yunnan,China,665099[16]People's Hospital Of RuiAn City,Rui'an,Zhejiang,China,325200
研究目的：
This study uses random, double -blindness, placebo control, and phase multi -center test design. All subjects who meet the standards receive TQ-A3334 per tablet/placebo nucleoside (acid) analog. A total of 116 subjects are needed.
